155 related articles for article (PubMed ID: 33753109)
1. Potent in vitro antitumor activity of B-subunit of Shiga toxin conjugated to the diphtheria toxin against breast cancer.
Mohseni Z; Sedighian H; Halabian R; Amani J; Behzadi E; Imani Fooladi AA
Eur J Pharmacol; 2021 May; 899():174057. PubMed ID: 33753109
[TBL] [Abstract][Full Text] [Related]
2. [Construction and expression of the fusion protein DT389-hIL-13 and its cytotoxicity to glioma cell lines].
Tuo HZ; Wang JW; Wang DX; Li JM; Ouyang J; Hong T
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(12):1024-8. PubMed ID: 15312540
[TBL] [Abstract][Full Text] [Related]
3. Gastric Adenocarcinomas Express the Glycosphingolipid Gb3/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit.
Geyer PE; Maak M; Nitsche U; Perl M; Novotny A; Slotta-Huspenina J; Dransart E; Holtorf A; Johannes L; Janssen KP
Mol Cancer Ther; 2016 May; 15(5):1008-17. PubMed ID: 26826119
[TBL] [Abstract][Full Text] [Related]
4. Designing and Analyzing the Structure of DT-STXB Fusion Protein as an Anti-tumor Agent: An
Mohseni Moghadam Z; Halabian R; Sedighian H; Behzadi E; Amani J; Imani Fooladi AA
Iran J Pathol; 2019; 14(4):305-312. PubMed ID: 31754360
[TBL] [Abstract][Full Text] [Related]
5. Expression, purification, characterization, and cytotoxic evaluation of the ML1-STxB fusion protein.
Yousefi MH; Afkhami H; Akbari A; Honari H
Arch Microbiol; 2023 May; 205(6):220. PubMed ID: 37148384
[TBL] [Abstract][Full Text] [Related]
6. A real-time cell-binding assay reveals dynamic features of STxB-Gb3 cointernalization and STxB-mediated cargo delivery into cancer cells.
Encarnação JC; Napolitano V; Opassi G; Danielson UH; Dubin G; Popowicz GM; Munier-Lehmann H; Buijs J; Andersson K; Björkelund H
FEBS Lett; 2020 Aug; 594(15):2406-2420. PubMed ID: 32473599
[TBL] [Abstract][Full Text] [Related]
7. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity.
Vingert B; Adotevi O; Patin D; Jung S; Shrikant P; Freyburger L; Eppolito C; Sapoznikov A; Amessou M; Quintin-Colonna F; Fridman WH; Johannes L; Tartour E
Eur J Immunol; 2006 May; 36(5):1124-35. PubMed ID: 16568496
[TBL] [Abstract][Full Text] [Related]
8. Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds.
Stimmer L; Dehay S; Nemati F; Massonnet G; Richon S; Decaudin D; Klijanienko J; Johannes L
BMC Cancer; 2014 Dec; 14():916. PubMed ID: 25476116
[TBL] [Abstract][Full Text] [Related]
9. Repurposing the Pentameric B-Subunit of Shiga Toxin for Gb3-Targeted Immunotherapy of Colorectal Cancer by Rhamnose Conjugation.
Liu Z; Li X; Lu Z; Qin X; Hong H; Zhou Z; Pieters RJ; Shi J; Wu Z
J Pharm Sci; 2022 Oct; 111(10):2719-2729. PubMed ID: 35905973
[TBL] [Abstract][Full Text] [Related]
10. Membrane invagination induced by Shiga toxin B-subunit: from molecular structure to tube formation.
Pezeshkian W; Hansen AG; Johannes L; Khandelia H; Shillcock JC; Kumar PB; Ipsen JH
Soft Matter; 2016 Jun; 12(23):5164-71. PubMed ID: 27070906
[TBL] [Abstract][Full Text] [Related]
11. Tumor delivery of ultrasound contrast agents using Shiga toxin B subunit.
Couture O; Dransart E; Dehay S; Nemati F; Decaudin D; Johannes L; Tanter M
Mol Imaging; 2011 Apr; 10(2):135-43. PubMed ID: 21439258
[TBL] [Abstract][Full Text] [Related]
12. Analyzing of expression of novel polypeptide complexes consisting of Shiga toxin B subunit and Adherence Fimbriae of Escherichia coli based on in silico modeling.
Noroozian Z; Oloomi M; Bouzari S
J Mol Model; 2012 Sep; 18(9):4131-9. PubMed ID: 22527278
[TBL] [Abstract][Full Text] [Related]
13. Trafficking of Shiga toxin/Shiga-like toxin-1 in human glomerular microvascular endothelial cells and human mesangial cells.
Warnier M; Römer W; Geelen J; Lesieur J; Amessou M; van den Heuvel L; Monnens L; Johannes L
Kidney Int; 2006 Dec; 70(12):2085-91. PubMed ID: 17063173
[TBL] [Abstract][Full Text] [Related]
14. B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity.
Adotevi O; Vingert B; Freyburger L; Shrikant P; Lone YC; Quintin-Colonna F; Haicheur N; Amessou M; Herbelin A; Langlade-Demoyen P; Fridman WH; Lemonnier F; Johannes L; Tartour E
J Immunol; 2007 Sep; 179(5):3371-9. PubMed ID: 17709554
[TBL] [Abstract][Full Text] [Related]
15. Design of a recombinant immunotoxin against the human granulocyte-colony stimulating factor receptor.
Babavalian E; Zeinoddini M; Saeedinia AR; Mohammadi R; Xodadadi N
Mol Biol Rep; 2019 Feb; 46(1):1093-1097. PubMed ID: 30565075
[TBL] [Abstract][Full Text] [Related]
16. Modification in media composition to obtain secretory production of STxB-based vaccines using Escherichia coli.
Sadraeian M; Ghoshoon MB; Mohkam M; Karimi Z; Rasoul-Amini S; Ghasemi Y
Virol Sin; 2013 Feb; 28(1):43-8. PubMed ID: 23329470
[TBL] [Abstract][Full Text] [Related]
17. Investigate the immunogenic and protective effect of trivalent chimeric protein containing IpaD-StxB-TolC antigens as a vaccine candidate against S. dysenteri and S. flexneri.
Fathi J; Amani J; Nazarian S; Hadi N; Mirhosseini SA; Ranjbar R; Abianeh HS
Microb Pathog; 2023 May; 178():106066. PubMed ID: 36924900
[TBL] [Abstract][Full Text] [Related]
18. Differential recognition of lipid domains by two Gb3-binding lectins.
Schubert T; Sych T; Madl J; Xu M; Omidvar R; Patalag LJ; Ries A; Kettelhoit K; Brandel A; Mely Y; Steinem C; Werz DB; Thuenauer R; Römer W
Sci Rep; 2020 Jun; 10(1):9752. PubMed ID: 32546842
[TBL] [Abstract][Full Text] [Related]
19. Production and evaluation of cytotoxic effects of DT386-BR2 fusion protein as a novel anti-cancer agent.
Shafiee F; Rabbani M; Jahanian-Najafabadi A
J Microbiol Methods; 2016 Nov; 130():100-105. PubMed ID: 27609715
[TBL] [Abstract][Full Text] [Related]
20. Intracellular trafficking of Shiga-toxin-B-subunit-functionalized spherulites.
Bouter A; Delord B; Dransart E; Poirier C; Johannes L; van Effenterre D
Biol Cell; 2008 Dec; 100(12):717-25. PubMed ID: 18564063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
